Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese Pulmonary Vascular Disease Research Group
About this trial
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥18 years old
Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS & PUMC, Beijing, China
Disqualifiers
Patients without RHC
The quality of routine examinations and RHC cannot meet the requirement for further analysis
Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Trial population
Adult patients previously received chest X-rays, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China.
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Right heart catheterization
Diagnostic testRHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
Treatment groups
2,000 Participants
are divided into 2 treatment groupsGroup A: Patients with pulmonary hypertension1 intervention
Group B: Patients without pulmonary hypertension1 intervention
Trial outcomes
Primary outcomes
1
Accuracy of diagnosis by artificial intelligence-assisted algorithm
The investigators will calculate the area under the receiver operating characteristic curve of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame
BaselineSecondary outcomes
1
Sensitivity of diagnosis by artificial intelligence algorithm
The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame
Baseline2
Specificity of diagnosis by artificial intelligence algorithm
The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov